Immunochromatography time resolution fluorescence kit for synchronously detecting mixed pollution of five types of fungi toxins fungaltoxin of aflatoxin and the like and application
A time-resolved fluorescence and aflatoxin technology, applied in fluorescence/phosphorescence, analytical materials, measurement devices, etc., can solve problems such as high requirements, poor reproducibility, and complicated sample pretreatment process
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Example Embodiment
[0040] Example 1 Obtaining aflatoxin B1 monoclonal antibody
[0041] The universal monoclonal antibody to aflatoxin is secreted and produced by the hybridoma cell line 3G1 with the deposit number CCTCC NO.C201014, and is specifically prepared in advance according to the method reported in the patent with the grant number ZL201210117614.9. The preparation method is: The tumor cell line 3G1 was injected with BALB / c mice pre-treated with Freund’s incomplete adjuvant, and the ascites of the mice were collected and purified to obtain aflatoxin B1 monoclonal antibody. Among them, the purification method is the caprylic acid-ammonium sulfate method, the specific operation is: filter the mouse ascites with double-layer filter paper, centrifuge the filtered ascites at 4℃, 12000r / min for more than 15 minutes, aspirate the supernatant, and mix the supernatant with 4 times the volume Acetate buffer solution mixed, slowly add n-octanoic acid while stirring, the volume of n-octanoic acid requi...
Example Embodiment
[0043] Example 2 Obtaining of Monoclonal Antibodies to Ochratoxin A
[0044] The ochratoxin A monoclonal antibody is secreted and produced by the hybridoma cell line 1H2 with the deposit number CCTCC NO.C201329, and is specifically prepared in advance according to the method reported in the patent application number 201310115921.8. The preparation method is: the hybridoma cell line 1H2 It was injected into the abdomen of BALB / c mice pretreated with Freund's incomplete adjuvant, and the ascites of the mice were collected and purified to obtain ochratoxin A monoclonal antibody. The described purification method is the caprylic acid-ammonium sulfate method, and the specific steps are: filter the mouse ascites with double-layer filter paper, centrifuge at 12000r / min for more than 15 minutes at 4°C, absorb the supernatant, and mix the resulting ascites serum with 4 times the volume of vinegar Mix acid salt buffer, slowly add n-octanoic acid under stirring, the volume of n-octanoic aci...
Example Embodiment
[0046] Example 3 Obtaining of Zearalenone monoclonal antibody
[0047] The zearalenone monoclonal antibody is secreted and produced by the hybridoma cell line 2D3 with the deposit number CCTCC NO.C201328, and is specifically prepared in advance according to the method reported in the patent application number 201310115825.3. The preparation method is: 2D3 was injected into the abdomen of BALB / c mice pretreated with Freund’s incomplete adjuvant, and the ascites of the mice were collected and purified to obtain the zearalenone monoclonal antibody; the purification method is caprylic acid-ammonium sulfate Method, the specific steps are: filter the mouse ascites with double-layer filter paper, centrifuge at 12000r / min for more than 15 minutes at 4℃, aspirate the supernatant, mix the resulting ascites serum with 4 times the volume of acetate buffer, and slowly add under stirring Octanoic acid, the required volume of n-octanoic acid per milliliter of ascites is 30-35μL, mix at room tem...
PUM
Property | Measurement | Unit |
---|---|---|
Sensitivity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap